Methyl 2-phenyl-2-piperidin-1-ylacetate;hydrochloride | 4412-19-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl 2-phenyl-2-piperidin-1-ylacetate;hydrochloride
• CAS: 4412-19-5
• 化学式: C14H20ClNO2
• 分子量: 269.77
• InChiKey: PDFYHZNGYUJTRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.81
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Method for treating sleep-related breathing disorders
  申请人：Rao G. Srinivas

  公开号：US20060039866A1

  公开（公告）日：2006-02-23

  Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include mirtazapine in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.

  本研究提供了用于治疗睡眠相关呼吸障碍的组合物和方法。组合物包括米氮平与其他活性药物成分（如唑尼沙胺、托吡酯或莫达非尼）的组合。治疗的睡眠相关呼吸障碍包括睡眠呼吸暂停和睡眠呼吸减弱。在某些实施方案中，药物化合物用作气道正压疗法的辅助疗法，从而降低气道正压疗法期间维持气道通畅所需的压力。
• JPH1143486A
  申请人：——

  公开号：JPH1143486A

  公开（公告）日：1999-02-16
• Method for treating sleep-related breathing disorders with setiptiline
  申请人：Rao G. Srinivas

  公开号：US20060039867A1

  公开（公告）日：2006-02-23

  Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include setiptiline in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.
• PHARMACEUTICAL PREPARATIONS FOR ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER AND OTHER ASSOCIATED DISORDERS
  申请人：Fallon M. Joan

  公开号：US20070116695A1

  公开（公告）日：2007-05-24

  A pharmaceutical preparation for the treatment of attention deficit disorders combines a therapeutically effective amount of digestive enzymes, such as chymotrypsin, and medication used to treat attention deficit disorders, such as Ritalin®, Concert®, Adderall® and Strattera®. The preparation may be in the form of a tablet, capsule or time released formula in order to reduce the amount of pills per dosage. The pharmaceutical preparation ameliorates the symptoms of the attention deficit disorder. The preparation has a stabilizing matrix containing a solidified microcrystalline cellulose which captures and protects therapeutically effective amounts of digestive enzyme particles within the stabilizing matrix.
• EXTENDED RELEASE OSMOTIC DOSAGE FORM COMPRISING HIGH METHYLPHENIDATE HYDROCHLORIDE LOAD
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20180360817A1

  公开（公告）日：2018-12-20

  The present invention provides an extended release osmotic tablet dosage form comprising methylphenidate hydrochloride (MPH). The dosage form comprises a core tablet comprising methylphenidate hydrochloride in an amount of more than 8% by weight of the core tablet; a semi-permeable membrane surrounding the core tablet, and an immediate release drug coat comprising methylphenidate hydrochloride surrounding the semipermeable membrane.